Doctors' perceptions of psoriasis therapies vary

Doctors' perceptions of psoriasis therapies vary
Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal of the American Academy of Dermatology.

(HealthDay)—Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal of the American Academy of Dermatology.

Katrina Abuabara, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues surveyed 246 members of the National Psoriasis Foundation and 141 members of the American Academy of Dermatology about the safety and effectiveness of psoriasis treatments.

The researchers found that , ustekinumab, cyclosporine, and adalimumab were regarded as being most likely to clear skin in three months (67 to 75 percent). Etanercept, , ultraviolet B, and ustekinumab were regarded as being the least likely to produce side effects requiring discontinuation of treatment (9 to 11 percent). In both cases, up to 49 percent "didn't know" the effectiveness or the likelihood of side effects, and the coefficients of variation were higher for the perceived likelihood of side effects. There were few significant correlations between perceptions and respondent characteristics, and perceptions could not be consistently predicted by treatment preference.

"Psoriasis providers demonstrate wide variation in their perception of the effectiveness and especially safety of systemic treatments," Abuabara and colleagues conclude.

Several authors disclosed to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Study compares effectiveness of psoriasis treatments

Apr 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of ...

Reasons for discontinuation vary by psoriasis treatment

Aug 10, 2012

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Many psoriasis patients undertreated for CV risk factors

Jun 22, 2012

(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue ...

Recommended for you

UN chief: Ebola cases in Mali a 'deep concern'

8 hours ago

The United Nations chief warned Friday that Ebola may be easing in part of West Africa but is still hitting hard in other areas and outpacing the international response.

Ebola death toll rises to 5,459: WHO

14 hours ago

The World Health Organization said Friday that 5,459 people had so far died of Ebola out of a total 15,351 cases of infection in eight countries since late December 2013.

Flu season off to a slow start ... for now

17 hours ago

(HealthDay)—This year's flu season is off to a slow but detectable start. And it appears to be a typical one that's likely to peak in January or February, a leading U.S. health official says.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.